Samil Pharmaceutical Co.,Ltd

KSE 000520.KS

Samil Pharmaceutical Co.,Ltd EPS (Diluted) for the year ending December 31, 2023: USD 0.09

Samil Pharmaceutical Co.,Ltd EPS (Diluted) is USD 0.09 for the year ending December 31, 2023, a 5,624.98% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.

Samil Pharmaceutical Co.,Ltd EPS (Diluted) for the year ending December 31, 2022 was USD -0.00, a 99.50% change year over year.
Samil Pharmaceutical Co.,Ltd EPS (Diluted) for the year ending December 31, 2021 was USD -0.32, a -453.58% change year over year.
Samil Pharmaceutical Co.,Ltd EPS (Diluted) for the year ending December 31, 2020 was USD 0.09, a 81.34% change year over year.
Samil Pharmaceutical Co.,Ltd EPS (Diluted) for the year ending December 31, 2019 was USD 0.05, a 107.66% change year over year.

Key data

Date	EPS (Diluted)	Shares (Diluted, Weighted)	Shares (Basic, Weighted)	Revenue

KSE: 000520.KS

Samil Pharmaceutical Co.,Ltd

CEO	Mr. Kang Huh
IPO Date	Jan. 4, 2000
Location	South Korea
Headquarters	155 Hyoryeong-Ro
Employees	586
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Samil Pharmaceutical Co.,Ltd engages in the manufacture and sale of indispensable medicines in South Korea. It offers hepatic, gastrointestinal, vasodilator, antithrombotic, respiratory, skeletal muscle relaxants, circulatory, neurological, antibiotics, metabolic, antihistamines, immunosuppressive, hormone, anti-tumor, urinary, and ophthalmic drugs, as well as antipyretic, analgesic, and anti-inflammatory agents. The company also provides OTC products and sanitary aids. Samil Pharmaceutical Co.,Ltd was founded in 1947 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years